- Home
- ICU vs ATHA Comparison
ICU vs ATHA Comparison
Compare ICU & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- ATHA
- Stock Information
- Founded
- ICU 2018
- ATHA 2011
- Country
- ICU United States
- ATHA United States
- Employees
- ICU N/A
- ATHA N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- ICU Health Care
- ATHA Health Care
- Exchange
- ICU Nasdaq
- ATHA Nasdaq
- Market Cap
- ICU 10.4M
- ATHA 10.6M
- IPO Year
- ICU N/A
- ATHA 2020
- Fundamental
- Price
- ICU $0.32
- ATHA $0.30
- Analyst Decision
- ICU
- ATHA Buy
- Analyst Count
- ICU 0
- ATHA 4
- Target Price
- ICU N/A
- ATHA $11.25
- AVG Volume (30 Days)
- ICU 1.2M
- ATHA 1.3M
- Earning Date
- ICU 08-12-2025
- ATHA 07-31-2025
- Dividend Yield
- ICU N/A
- ATHA N/A
- EPS Growth
- ICU N/A
- ATHA N/A
- EPS
- ICU N/A
- ATHA N/A
- Revenue
- ICU $428,000.00
- ATHA N/A
- Revenue This Year
- ICU $754.07
- ATHA N/A
- Revenue Next Year
- ICU $100.09
- ATHA N/A
- P/E Ratio
- ICU N/A
- ATHA N/A
- Revenue Growth
- ICU N/A
- ATHA N/A
- 52 Week Low
- ICU $0.31
- ATHA $0.22
- 52 Week High
- ICU $13.85
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- ICU 10.59
- ATHA 47.38
- Support Level
- ICU $0.31
- ATHA $0.29
- Resistance Level
- ICU $1.30
- ATHA $0.35
- Average True Range (ATR)
- ICU 0.10
- ATHA 0.03
- MACD
- ICU -0.09
- ATHA -0.00
- Stochastic Oscillator
- ICU 1.11
- ATHA 23.51
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.